Abstract: A method is disclosed for counteracting a decrease in nitrogen balance and counteracting a decrease in protein synthesis in an individual, comprising administering to the individual a combination of insulin and IGF-I.
Type:
Grant
Filed:
December 18, 1996
Date of Patent:
May 26, 1998
Assignee:
Pharmacia & Upjohn AB
Inventors:
Vibeke Arrhenius-Nyberg, Kjell Malmlof, Anna Skottner
Abstract: A composition comprising coagulation factor VIII and a non-ionic surfactant such as block copolymers, e.g., polyoxamers or polyoxyethylene (20) sorbitan fatty acid esters, e.g., polysorbate 20 or polysorbate 80 as stabilizer is provided. The composition can also comprise sodium chloride, calcium chloride, L-histidine and/or sugars or sugar alcohols.
Abstract: A method for treating conditions responsive to nicotine therapy, and particularly for smoking cessation therapy and for reducing nicotine craving, is described that utilizes transdermal nicotine delivery for obtaining base-line nicotine plasma levels coupled with transmucosal administration of nicotine to satisfy transient craving.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
February 24, 1998
Assignee:
Pharmacia & Upjohn AB
Inventors:
Richard W. Baker, Giancarlo Santus, Susan Vintilla-Friedman
Abstract: The present invention is directed to a drug containing non-reusable syringe having a hollow plunger rod provided with a rupture line for permanently detaching its rear part which can be engaged with the needle holder to perform a radial motion that breaks the needle which thereafter is received by a cavity in the rear part of the detached plunger rod. The rear part of the plunger rod can also be attached to the needle holder to protect the user from accidental needle sticks.
Abstract: Processes for refolding of insulin-like growth factor (IGF) comprise contacting IGF in a reduced or misfolded form with insulin-like growth factor binding protein (IGF-BP), and recovering native IGF.
Abstract: A composition for administration to the nasal mucosa of a subject comprises a solution of nicotine or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable solvent. The composition has a nicotine concentration in the range of about 10 to about 40 mg/ml and contains a suitable agent to produce a viscosity in the range of about 1 to about 30 centipoise. The composition assists in reduction of the desire of the subject to smoke tobacco or provides a substitute for tobacco smoking.
Abstract: A product containing a) glutamine, L-amino acid of glutamine, N-acetyl-L-glutamine and/or glutamine-containing peptide;b) fatty acid containing 2-12 carbon atoms; andc) IGF-1 is useful for treating patients for atrophy of the gut mucosa.
Type:
Grant
Filed:
May 5, 1995
Date of Patent:
July 8, 1997
Assignee:
Pharmacia & Upjohn AB
Inventors:
Reinhold Kihlberg, Svante Bengt Lindgren, Lars Goran Sandberg
Abstract: The invention relates to the use of, and methods to obtain, ion exchanger complexes with psychotropic drugs for reducing toxic side effects and lethality when overdosing the drug. The invention includes methods and compositions for modifying the total amount of drug released from the complex in the gastro-intestinal tract by adding a substance which affects the ion exchange process. The additional substance may be a salt which generates an ion with higher or similar affinity to the ion exchanger when compared to the drug. The additional substance may be a counter ion in an additional complex with an ion exchanger.
Type:
Grant
Filed:
June 21, 1994
Date of Patent:
July 1, 1997
Assignee:
Pharmacia & Upjohn AB
Inventors:
Carl-Aage Bergwitz-Larsen, deceased, Bertil Hillgren Ulf, Anders Ragnarsson Gert
Abstract: A lipid carrier system for a local anaesthetic comprising a defined lipid system of at least two lipid components wherein at least one of the lipid components is amphiphatic and polar and one is nonpolar is provided. The system may further contain a hydrophilic solvent and additives or matrices for adapting it for administering to mucous membranes and for transdermally administering.
Type:
Grant
Filed:
November 23, 1994
Date of Patent:
June 3, 1997
Assignee:
Pharmacia & Upjohn AB
Inventors:
H.ang.kan Nyqvist, Gert Ragnarsson, Per Tingvall
Abstract: The present invention relates to pharmaceutical compostions containing a defined lipid system of at least two lipid components where at least one of the lipid components is amphiphatic and polar and one is nonpolar wherein the pharmaceutically active compound is a heparin or a fragment thereof. In the compositions a water containing solvent also is included in such an amount that discrete lipid particles are present, and said compositions can be adapted to various administration forms such as rectal, oral, buccal, transdermal etc.
Abstract: Emulsion comprising a lipoid as a hydrophobic phase dispersed in a hydrophilic phase, a poorly water-soluble photosensitizing compound, surfactant, and as a cosurfactant a salt of a bile acid is provided that is suitable for administering to a patient.
Abstract: The invention relates to a method for obtaining a higher product expression in a producing mammalian cell line characterized by treating the original cell line with itself according to a fusion protocol known in the art. The production of protein products is performed in mammalian tissue culture, and the product could be therapeutic proteins or other molecules intended for human use. In particular, this invention relates to the use of cell fusion methods to obtain a stable high producing cell line.
Abstract: A process for the manufacture of porous cellulose particles, which have regular shape, and a capacity of sorbing 1.5-9 times of their own weight of water, a tap bulk density of less than 0.85 g/ml is provided. The process for the manufacture of these porous cellulose matrices is performed by mechanically treating of hydrolyzed cellulose in a wet stage. The cellulose matrices have preferably a size of at least 0.1 mm and a tap bulk density of 0.1-0.7 g/ml. A bioactive substance or bioactive substances could be sorbed, precipitated or sublimized into the porous structure of the matrices. The matrices can be admixed with drugs or drug containing granules in order to improve the tabletting and tablet properties and thereafter compressed.Drug loaded matrices can be used for direct compression of tablets.
Type:
Grant
Filed:
December 23, 1994
Date of Patent:
March 4, 1997
Assignee:
Pharmacia & Upjohn AB
Inventors:
Bo R. Ek, Kjell G. Eriksson, Per Gustaf H. Nyqvist, Gert A. Ragnarsson
Abstract: The present invention is directed to the use of taxol or a pharmaceutically and ophthalmologically acceptable derivative thereof for the prevention of secondary cataracts after extracapsular extraction with or without intraocular lens implantation.
Type:
Grant
Filed:
February 26, 1996
Date of Patent:
November 19, 1996
Assignee:
Pharmacia & Upjohn AB
Inventors:
Per M.ang.nsson, Wenche Rolfsen, Kerstin Wickstr om